Document:

<PAGE>

                                                                   EXHIBIT 10.28

                   Non-Employee Director Compensation Summary

      Boston Life Sciences, Inc.'s (the "Company's") non-employee directors
currently consist of: (i) Robert S. Langer, Jr.; (ii) Michael J. Mullen; and
(iii) John T. Preston.

      In the third quarter of 2005, the Board of Directors amended the Company's
non-employee director compensation as follows:

<TABLE>
<CAPTION>
                                                                                  Annual Fee Per
                           2006 Annual Retainer      Per Board Meeting Fees      Committee Chaired
                           --------------------      ----------------------      -----------------
<S>                        <C>                       <C>                         <C>
Robert S. Langer, Jr.            $22,000                     $2,000                   $10,000
Michael J. Mullen                $22,000                     $2,000                   $20,000
John T. Preston                  $22,000                     $2,000                   $10,000
</TABLE>

      All non-employee directors are reimbursed for ordinary and reasonable
expenses of attending any board or committee meetings.

      Each new non-employee director is automatically granted an option to
purchase 15,000 shares of the Company's common stock ("New Director Options")
upon initial election or appointment (the "Automatic Grant Date"). The exercise
price of any New Director Options granted shall equal the fair market value of
shares of the Company's common stock subject thereto on the Automatic Grant
Date. New Director Options immediately vest as to 1/3 of the shares with the
remaining 2/3 of the shares subject to such New Director Option vesting in equal
monthly installments over two years ("New Director Option Vesting").

      Each non-employee director is automatically granted an option to purchase
10,000 shares of the Company's common stock ("Annual Director Options"). The
Annual Director Options are granted in the fourth quarter of each calendar year
(the "Annual Grant Date"). The exercise price of any Annual Director Options
granted shall equal the fair market value of shares of the Company's common
stock subject thereto on the Annual Grant Date. Annual Director Options vest in
equal monthly installments over two years ("Annual Director Option Vesting").
Newly elected non-employee directors are eligible to receive the Annual Director
Options in the fourth quarter of the second calendar year of service. On
December 12, 2005, Messrs. Mullen, Langer and Preston were each granted options
to purchase 10,000 shares of common stock under this policy with an exercise
price of $2.00 per share.

      If the Company appoints a non-employee chairman, the chairman will be
entitled to an annual retainer of $50,000 (in lieu of the $22,000 that is
received by the other non-employee directors) and per board meeting fees of
$2,000. The non-employee chairman will be automatically granted an option to
purchase 30,000 shares of the Company's common stock upon appointment (in lieu
of the 15,000 shares that is received by the other non-employee directors)
vesting in accordance with the New Director Option Vesting. In addition, the
non-employee chairman will be automatically granted an option to purchase 20,000
shares of the Company's common stock on the Annual Grant Date vesting in
accordance with the Annual Director Option Vesting. The newly elected
non-employee chairman is entitled to receive this annual grant in the fourth
quarter of the second calendar year of service. The exercise price of any
options granted to a non-employee chairman shall equal the fair market value of
shares of the Company's common stock subject thereto on the grant date.<PAGE>

                                                                   EXHIBIT 10.29

                     Executive Officer Compensation Summary

      Boston Life Sciences, Inc.'s (the "Company's") executive officers consist
of: (i) Peter G. Savas, Chairman and Chief Executive Officer; (ii) Mark J.
Pykett, President and Chief Operating Officer; and (iii) Kenneth L. Rice, Jr.,
Executive Vice President, Finance and Administration, Chief Financial Officer
and Secretary.

      The Company's compensation program for its executive officers consists of
four parts: base salary, annual bonus, stock options and additional benefits.
The Company's overall recruitment and compensation philosophy is a very
important consideration in the maintenance of this program. The Company seeks to
hire individuals possessing excellent professional skills, coupled with
demonstrated track records, who can be expected to help achieve the Company's
goal of moving from a development-stage company to a broad-based, diversified,
revenue-generating biotechnology company.

      The Compensation Committee of the Board of Directors (the "Committee")
seeks to establish base salaries for each position and level of responsibility
at a competitive level, sufficient to recruit and retain individuals possessing
the skills and experience necessary to achieve the Company's goals and
objectives over the long term. Base salary levels are generally established with
the input of various industry-related surveys and special studies as well as by
monitoring developments in the biotechnology industry. Annual cash bonuses
and/or incentive payments may be awarded to executive officers and the Company
expects to pay such amounts based on both an evaluation of the performance of
each executive officer for the year as a whole, as well as the establishment of
performance incentives for the following year dependent upon the realization of
specific corporate objectives. Options under the Company's stock option plans
are granted to all executive officers as incentive to contribute significantly
to the growth and successful operation of the Company. The specific
determination of the number of options to be granted, however, is not based upon
any specific criteria, although the Committee does reference industry data in
assessing the reasonableness of all awards.

      On March 31, 2006, the Company entered into employment agreements with
each of Messrs. Savas, Pykett and Rice effective January 1, 2006 as follows:

      Mr. Savas. On September 8, 2004, Mr. Savas joined the Company as Chairman
and Chief Executive Officer. Mr. Savas' employment agreement is effective for a
term of one year, provides for a base salary of $400,000 per year plus other
benefits and includes confidentiality and non-competition provisions. The
Committee approved a bonus of $100,000 for 2005. Subject to certain
contingencies, Mr. Savas is entitled to a one-year severance allowance in the
event that he is terminated in certain circumstances. The Agreement
automatically renews for an additional 12 month period, unless either party
notifies the other party in writing not less than 90 days prior to expiration.
In addition, on January 10, 2006, Mr. Savas was granted an option to purchase
350,000 shares of the Company's common stock at an exercise price of $2.50 per
share, vesting monthly as to 1/96th of the shares granted thereunder, subject to
accelerated vesting if certain performance goals are achieved. In addition, on
March 11, 2005, Mr. Savas was granted an option to purchase 200,000 shares of
the Company's common stock at an exercise price of $2.31 per share, of which 33%
immediately vested and the remaining 67% will vest in equal monthly installments
over three years.

      Mr. Pykett. On November 1, 2004, Mr. Pykett joined the Company as
Executive Vice President and Chief Operating Officer and on February 3, 2005 was
appointed President and remained Chief Operating Officer. Mr. Pykett's
employment agreement is effective for a term of one year, provides for a base
salary of $300,000 per year plus other benefits and includes confidentiality and
non-competition provisions. The Committee approved a bonus of $68,750 for 2005.
Subject to certain contingencies, Mr. Pykett will be entitled to a nine-month
severance allowance in the event that he is terminated in certain circumstances.
The Agreement automatically renews for an additional 12 month period, unless
either party notifies the other party in writing not less than 90 days prior to
expiration. In addition, on January 10,

<PAGE>

2006, Mr. Pykett was granted an option to purchase 225,000 shares of the
Company's common stock at an exercise price of $2.50 per share, vesting monthly
as to 1/96th of the shares granted thereunder, subject to accelerated vesting if
certain performance goals are achieved. In addition, on March 11, 2005, Mr.
Pykett was granted an option to purchase 100,000 shares of the Company's common
stock at an exercise price of $2.31 per share, of which 33% immediately vested
and the remaining 67% will vest in equal monthly installments over three years.
In addition, on February 4, 2005, Mr. Pykett was granted an option to purchase
100,000 shares of the Company's common stock at an exercise price of $3.75 per
share, of which 25% immediately vested and the remaining 75% will vest in equal
monthly installments over four years.

      Mr. Rice. On July 8, 2005, Mr. Rice joined the Company as Executive Vice
President, Finance and Administration and Chief Financial Officer. Mr. Rice's
employment agreement is effective for a term of one year, provides for a base
salary of $300,000 per year plus other benefits and includes confidentiality and
non-competition provisions. The Committee approved a bonus of $34,375 for 2005.
Subject to certain contingencies, Mr. Rice will be entitled to a nine-month
severance allowance in the event that he is terminated in certain circumstances.
The Agreement automatically renews for an additional 12 month period, unless
either party notifies the other party in writing not less than 90 days prior to
expiration. In addition, on January 10, 2006, Mr. Rice was granted an option to
purchase 225,000 shares of the Company's common stock at an exercise price of
$2.50 per share, vesting monthly as to 1/96th of the shares granted thereunder,
subject to accelerated vesting if certain performance goals are achieved. In
addition, on July 18, 2005, Mr. Rice was granted an option to purchase 300,000
shares of the Company's common stock at an exercise price of $3.25 per share, of
which 33% immediately vested and the remaining 67% will vest in equal monthly
installments over three years.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]